adult-onset Still's disease: adult-onset Still disease (AOSD) is a rare inflammatory multisystem disorder characterized clinically by fever of unknown origin, arthralgia or arthritis, hyperleucocytosis, and typical skin rash.
Endpoint definition
↥Report an error or suggest an improvement for this endpoint codes
Endpoint definition steps |
FinnGen |
|---|---|
Phenotype data |
519972 |
1. Apply sex-specific ruleNone |
519972 |
2. Check conditionsNone |
519972 |
3. Check pre-conditions, main-only, mode, registry filtersRegistry filters: 2 out of 7 registries used, show all original rules. |
154 |
4. Check minimum number of eventsNone |
154 |
5. Include endpointsNone |
154 |
6. Filter based on genotype QC (FinnGen only) |
147 |
Control definitions (FinnGen only)
- Control exclude
- ILD_SYST_AUTO_DISEASES
Extra metadata
- First used in FinnGen datafreeze
- DF5
- Parent code in ICD-10
- M06
- Name in latin
- Arthritis rheumatoides seronegativa
Similar endpoints
↥List of similar endpoints to
Adult-onset Still disease
based on the number of shared cases.
Similar with more cases:
- Other (seronegative) rheumatoid arthritis, wide
- Rheumatoid arthritis
- Rheumatoid arthritis, including avohilmo
- Polyarthropathies
- Autoimmune diseases related-to ILD
Similar with less cases:
None
Case counts by codes
↥
Summary Statistics
↥-FinRegistry-
Key figures
| All | Female | Male | |
|---|---|---|---|
| Number of individuals | |||
| Whole population | 695 | 385 | 303 |
| Only index persons | 637 | 353 | 284 |
| Unadjusted period prevalence (%) | |||
| Whole population | 0.01 | 0.01 | 0.01 |
| Only index persons | 0.01 | 0.01 | 0.01 |
| Median age at first event (years) | |||
| Whole population | 49.30 | 49.81 | 48.68 |
| Only index persons | 47.00 | 47.43 | 46.47 |
-FinnGen-
Key figures
| All | Female | Male | |
|---|---|---|---|
| Number of individuals | 147 | 92 | 55 |
| Unadjusted period prevalence (%) | 0.03 | 0.03 | 0.03 |
| Median age at first event (years) | 44.81 | 43.75 | 46.57 |
-FinRegistry-
Age distribution of first events
-FinnGen-
Age distribution of first events
-FinRegistry-
Year distribution of first events
-FinnGen-
Year distribution of first events
-FinRegistry-
Cumulative Incidence Function
-FinnGen-
Cumulative Incidence Function
No data
CodeWAS
↥CodeWAS is a tool for exploring the associations between an endpoint and all of the medical codes and drug codes.
This is a new tool, please reach out using the contact form for feedback and improvement ideas.
First, a cohort is built by matching controls to the endpoint cases using year of birth and sex. Then, a Fisher test is done for all the medical codes and drug codes between the cases and controls of this cohort. Codes are reported in the table below if they have −log10(p-value) ≥ 6.
Matched cohort
- Matched cases
- 154
- Matched controls
- 1540
Code
Vocabulary
Description
Odds Ratio
-log10(p)
N matched cases
N matched controls
M06.1
ICD-10 Finland
Adult-onset Still disease
+∞
222.6
154
*
202
Kela drug reimbursment
Connective tissue diseases, rheumatoid arthritis and comparable disease
67.5
159.1
110
55
L04AX03
ATC
methotrexate; systemic
38.3
117.9
91
56
L01BA01
ATC
methotrexate; systemic
93.7
114.7
62
11
M06.0
ICD-10 Finland
Seronegative rheumatoid arthritis
57.7
81.6
48
12
TNX10
NOMESCO Finland
Arthrocentesis, unspecified region, unspecified region
27.4
80.0
63
38
P01BA02
ATC
hydroxychloroquine; oral
19.3
69.6
67
59
NK4XE
NOMESCO Finland
Joint ultrasound examination not elsewhere classified
25.4
69.4
55
33
A07EC01
ATC
sulfasalazine; oral, rectal
23.9
66.5
54
34
R50.9
ICD-10 Finland
Fever, unspecified
13.0
59.0
86
137
313
Kela drug reimbursment
Abatacept, adalimumab, anakinra, certolizumab pegol, etanercept, golimumab, infliximab, ixekizumab, sarilumab, secukinumab, tocilizumab and ustekinumab (rheumatoid diseases)
159.7
52.7
53
5
M05BA04
ATC
alendronic acid; oral
17.8
50.0
46
36
M05.8
ICD-10 Finland
Other seropositive rheumatoid arthritis
18.3
49.9
45
34
A12AX
ATC
Calcium, combinations with vitamin D and/or other drugs
10.5
47.2
107
274
281
Kela drug reimbursment
Abatacept, adalimumab, anakinra, certolizumab pegol, etanercept, golimumab, infliximab, ixekizumab, sarilumab, secukinumab and tocilizumab
137.9
46.9
48
5
H02AB06
ATC
prednisolone; systemic
17.6
44.0
137
484
M13.9
ICD-10 Finland
Arthritis, unspecified
11.1
33.0
40
47
H02AB07
ATC
prednisone; oral
8.4
31.9
52
88
L04AC03
ATC
anakinra; parenteral
+∞
26.9
25
*
GD1AA
NOMESCO Finland
Thorax X-ray examination
5.7
24.9
102
395
NK6QA
NOMESCO Finland
Measurement of bone density from two or more locations with X-ray
9.4
23.9
32
42
M08.2
ICD-10 Finland
Juvenile arthritis with systemic onset
+∞
23.5
22
*
JN3AE
NOMESCO Finland
Abdominal ultrasound examination
6.5
22.5
45
92
M06.9
ICD-10 Finland
Rheumatoid arthritis, unspecified
28.3
22.3
30
13
A49.9
ICD-10 Finland
Bacterial infection, unspecified
7.0
21.3
38
69
L04AA13
ATC
[U] leflunomide
49.2
21.2
25
6
L04AX01
ATC
azathioprine; systemic
38.7
21.0
26
8
L88
ICPC
Rheumatoid/seropositive arthritis
25.2
20.9
29
14
L04AB04
ATC
adalimumab; parenteral
107.6
18.0
19
*
L04AA01
ATC
[U] ciclosporin
57.0
17.5
20
*
NF1AA
NOMESCO Finland
Hip X-ray examination
7.2
17.1
28
46
252, ,
Kela drug reimbursment
+∞
17.0
16
*
3053, ,
Kela drug reimbursment
+∞
15.9
15
*
M08.0
ICD-10 Finland
Juvenile rheumatoid arthritis
+∞
13.7
13
*
L04AD01
ATC
ciclosporin; systemic
31.6
13.3
17
6
ZX120
NOMESCO Finland
Intravenous
5.4
13.2
29
63
NH3DA
NOMESCO Finland
Bilateral foot X-ray examination
22.4
12.8
18
9
NH3AA
NOMESCO Finland
Foot and toes X-ray examination
5.5
12.2
26
55
ND2AA
NOMESCO Finland
Hand and fingers X-ray examination
4.8
12.1
31
77
ND2DA
NOMESCO Finland
Bilateral hand X-ray examination
18.3
12.0
18
11
L04AC07
ATC
tocilizumab; parenteral
+∞
11.6
11
*
L04AB01
ATC
etanercept; parenteral
47.0
11.1
13
*
7143A
ICD-9 Finland
Rheumatoid arthritis and other inflammatory polyarthropathies, Juvenile chronic polyarthritis[MB STILL]
+∞
10.5
10
*
M01CB01
ATC
sodium aurothiomalate; parenteral
35.2
10.5
13
*
NG1AA
NOMESCO Finland
Knee X-ray examination without contrast
4.4
10.3
29
77
TQX10
NOMESCO Finland
Biopsy of skin and subcutaneous tissue
5.1
10.2
23
51
UJD10
NOMESCO Finland
Esophagoscopy, gastroscopy and duodenoscopy
3.1
9.5
55
236
M08.3
ICD-10 Finland
Juvenile polyarthritis (seronegative)
+∞
9.5
9
*
NH3BA
NOMESCO Finland
Foot and toes extensive X-ray examination
9.3
9.4
19
23
A46
ICD-10 Finland
Erysipelas
4.2
9.3
28
78
A02BC02
ATC
pantoprazole; systemic
3.2
9.1
116
755
J01MA12
ATC
levofloxacin; systemic
3.3
9.0
42
158
NA3AA
NOMESCO Finland
Lumbar spine X-ray examination without contrast
4.5
9.0
24
61
NF1AE
NOMESCO Finland
Hip joint ultrasound examination
17.6
8.7
13
8
L04AB06
ATC
golimumab; parenteral
95.0
8.5
9
*
L04AA11
ATC
[U] etanercept
+∞
8.4
8
*
TPH04
NOMESCO Finland
Cathetrisation of vein
3.0
7.8
42
171
JN6DR
NOMESCO Finland
PET-CT of whole body metabolism
26.5
7.7
10
*
M06.8
ICD-10 Finland
Other specified rheumatoid arthritis
26.5
7.7
10
*
L30.9
ICD-10 Finland
Dermatitis, unspecified
3.0
7.6
41
167
L04AA14
ATC
[U] anakinra
+∞
7.3
7
*
208
Kela drug reimbursment
Ulcerative colitis and Crohn's disease
+∞
7.3
7
*
NH3EA
NOMESCO Finland
Feet X-ray examination with load
21.2
7.2
10
5
TNH11
NOMESCO Finland
Injection of diagnostic or therapeutic substance in ankle joint or foot joint
31.6
7.2
9
*
NDG30
NOMESCO Finland
Fusion of wrist, total
31.6
7.2
9
*
7140A
ICD-9 Finland
Rheumatoid arthritis and other inflammatory polyarthropathies, Rheumatoid arthritis[ARTHRITIS RHEUMATOIDES SEROPOSITIVA]
31.6
7.2
9
*
GD1DD
NOMESCO Finland
High resolution CT examination of lungs
6.7
7.0
17
28
ND2BA
NOMESCO Finland
Hand and fingers extensive X-ray examination
11.7
6.9
12
11
J18.9
ICD-10 Finland
Pneumonia, unspecified
2.7
6.7
43
191
R70.0
ICD-10 Finland
Elevated erythrocyte sedimentation rate
10.7
6.7
12
12
J01MA01
ATC
ofloxacin; systemic
4.3
6.6
18
46
D07AC01
ATC
betamethasone; topical
2.5
6.6
64
346
K51.9
ICD-10 Finland
Ulcerative colitis, unspecified
72.7
6.5
7
*
M45
ICD-10 Finland
Ankylosing spondylitis
27.9
6.3
8
*
291
Kela drug reimbursment
Tofacitinib
+∞
6.3
6
*
L04AA17
ATC
[U] adalimumab
+∞
6.3
6
*
7143C
ICD-9 Finland
Rheumatoid arthritis and other inflammatory polyarthropathies, Juvenile chronic polyarthritis[POLYARTHRITIS JUVENILIS SERONEGATIVA]
+∞
6.3
6
*
M06.4
ICD-10 Finland
Inflammatory polyarthropathy
+∞
6.3
6
*
UJF32
NOMESCO Finland
Coloscopy
2.7
6.2
41
184
H10
ICD-10 Finland
Conjunctivitis
4.0
6.1
18
49
JN1AE
NOMESCO Finland
Ultrasound examination of upper part of abdomen
3.6
6.1
21
64
NB1AA
NOMESCO Finland
Shoulder X-ray examination without contrast
3.9
6.1
19
54
NH1AA
NOMESCO Finland
Ankle X-ray examination without contrast
4.3
6.1
16
40
LabWAS
↥OMOP Concept
People with measurements
Mean N measurements
Mean measured value
(ID) Name
N Cases
N Controls
OR
-log10(p)
cases
controls
cases
controls
unit
-log10(p)
N cases
N controls
128
647
6.79
21.42
19.6
8.9
4.53
3.96
e9/l
1.47
122
563
108
530
4.47
17.23
8.7
2.5
248.66
95.90
ug/l
2.22
103
493
19
10
21.43
13.29
4.4
2.0
1215.32
1059.90
u/ml
—
19
10
135
877
5.37
12.62
17.0
6.5
70.33
76.31
u/l
1.23
130
826
21
20
11.96
11.69
1.3
1.4
—
—
—
0
0
20
18
12.58
11.43
1.3
1.3
302.13
142.00
u/ml
—
15
10
20
37
6.06
10.71
1.6
1.5
—
—
—
0
0
24
53
5.18
10.67
1.8
2.4
39.67
42.87
u/l
0.27
24
47
103
599
3.17
10.49
5.5
3.1
0.00
0.00
estimate
-0.00
21
109
101
594
3.03
9.84
5.5
3.0
0.00
0.00
estimate
-0.00
22
121
100
592
2.97
9.50
7.8
4.2
0.00
0.00
estimate
-0.00
21
113
87
490
2.78
8.90
8.0
5.6
1.21
1.22
mmol/l
0.70
77
422
17
19
9.90
8.80
2.1
1.3
—
—
—
0
0
77
410
2.76
8.75
5.2
3.8
33.57
36.75
g/l
3.46
72
391
32
104
3.62
8.58
1.7
1.6
—
—
—
0
0
73
384
2.71
8.42
4.5
2.6
—
—
—
0
0
41
158
3.17
8.39
2.3
1.8
—
—
—
0
0
14
12
12.69
8.26
4.1
2.0
4.66
4.46
e9/l
0.05
14
12
14
12
12.69
8.26
4.9
2.0
56.43
59.08
%
0.19
14
12
31
102
3.55
8.14
1.8
1.5
—
—
—
0
0
50
221
2.87
8.00
1.4
1.2
43.07
7.98
u/ml
1.18
22
87
27
83
3.73
7.82
1.5
1.2
137.64
151.49
u/ml
0.09
27
74
50
231
2.72
7.28
1.5
1.2
44.11
33.96
iu/ml
0.30
23
77
80
468
2.48
7.09
6.0
4.9
1.21
1.22
mmol/l
0.45
73
426
14
17
8.93
7.00
1.2
1.1
—
—
—
0
0
15
23
7.10
6.52
1.5
1.7
—
—
—
0
0
11
11
10.66
6.14
1.4
1.8
—
—
—
0
0
11
11
10.66
6.14
1.6
1.5
—
—
—
0
0
13
18
7.78
6.06
1.5
1.9
—
—
—
0
0
14
22
6.89
6.02
1.5
1.7
—
—
—
0
0
9
6
15.81
5.98
1.7
1.3
—
—
—
0
0
52
267
2.43
5.94
1.5
1.5
—
—
—
0
0
14
23
6.58
5.84
1.4
1.2
—
—
—
0
0
12
16
8.03
5.75
1.3
1.7
—
—
—
0
0
11
13
9.01
5.66
1.4
1.7
—
—
—
0
0
11
13
9.01
5.66
1.4
1.8
—
—
—
0
0
9
7
13.55
5.65
1.8
1.3
—
—
—
0
0
54
288
2.35
5.62
3.4
2.5
0.12
0.34
e6/l
1.38
44
210
16
33
5.29
5.62
1.8
1.5
—
—
—
0
0
14
25
6.05
5.52
1.4
1.8
—
—
—
0
0
46
234
2.38
5.29
3.8
1.9
2.84
3.24
mg/l
0.58
40
196
15
36
4.50
4.66
1.1
1.3
—
—
—
0
0
9
11
8.60
4.63
1.3
1.2
—
—
—
0
0
9
11
8.60
4.63
1.3
1.2
—
—
—
0
0
9
11
8.60
4.63
1.3
1.2
—
—
—
0
0
9
11
8.60
4.63
1.3
1.2
—
—
—
0
0
9
11
8.60
4.63
1.3
1.2
—
—
—
0
0
7
5
14.57
4.62
1.6
1.4
—
—
—
0
0
8
9
9.30
4.33
1.3
1.0
—
—
—
0
0
12
25
5.11
4.28
1.8
1.3
0.00
0.00
g/l
-0.00
12
25
54
320
2.06
4.15
5.6
3.2
0.00
0.00
estimate
-0.00
21
110
14
36
4.17
4.12
1.0
1.1
—
—
—
0
0
6
5
12.40
3.79
2.0
1.2
—
—
—
0
0
34
174
2.22
3.77
2.9
2.3
1.21
0.99
e6/l
0.15
20
94
143
1239
3.16
3.63
32.6
10.6
26.67
21.60
mg/l
0.93
132
926
9
17
5.55
3.57
1.0
1.1
—
—
—
0
0
6
6
10.33
3.52
2.3
2.7
—
—
—
0
0
63
413
1.89
3.52
4.4
3.2
23.23
27.26
ng/l
0.20
47
248
9
18
5.24
3.42
1.2
1.8
—
—
—
0
0
9
18
5.24
3.42
1.2
1.8
—
—
—
0
0
23
106
2.38
3.22
3.0
3.0
—
—
—
0
0
14
50
2.98
3.18
5.6
4.8
26.10
25.48
mmol/l
0.17
14
50
19
81
2.54
3.13
2.4
2.3
0.21
0.23
g/l
0.40
19
73
6
8
7.74
3.08
1.2
1.4
—
—
—
0
0
6
8
7.74
3.08
1.2
1.6
—
—
—
0
0
6
8
7.74
3.08
1.2
1.6
—
—
—
0
0
5
5
10.27
3.00
1.0
1.0
85.80
96.20
%
—
5
5
15
59
2.71
2.88
4.9
2.8
2.09
1.37
mmol/l
—
10
51
30
162
2.06
2.88
2.6
2.4
2.32
3.53
e6/l
0.42
16
83
8
18
4.63
2.83
1.1
1.5
—
—
—
0
0
8
18
4.63
2.83
1.1
1.5
—
—
—
0
0
8
18
4.63
2.83
3.4
2.3
24.55
25.91
mmol/l
—
8
18
11
34
3.40
2.79
3.5
1.9
—
—
—
0
0
5
6
8.56
2.77
1.4
1.3
—
—
—
0
0
16
67
2.55
2.73
2.0
1.4
—
—
—
0
0
20
94
2.30
2.69
1.2
1.1
41.11
154.75
iu/ml
—
7
35
65
463
1.70
2.58
10.7
8.4
1.20
1.15
inr
0.17
19
131
5
7
7.33
2.56
1.0
1.4
—
—
—
0
0
133
1163
2.05
2.47
23.0
9.9
87.75
86.97
ml/min/173m2
0.15
116
955
5
8
6.41
2.39
1.6
1.3
—
—
—
0
0
11
40
2.88
2.33
1.3
1.5
—
—
—
0
0
6
13
4.75
2.29
1.0
1.1
—
—
—
0
0
6
14
4.41
2.17
1.0
2.4
—
—
—
0
0
64
474
1.60
2.09
6.0
3.0
—
—
—
0
0
23
127
1.95
2.08
7.0
3.9
1.11
1.02
mmol/l
0.68
23
117
8
26
3.19
2.04
1.5
1.2
—
—
—
0
0
12
52
2.42
1.93
1.3
2.6
26048.62
789.01
u/l
—
5
18
40
270
1.65
1.87
2.9
2.1
—
—
—
0
0
6
17
3.63
1.85
2.0
1.4
—
—
—
0
0
5
12
4.27
1.83
1.0
1.1
—
—
—
0
0
9
35
2.67
1.83
1.3
1.2
—
—
—
0
0
7
23
3.14
1.82
2.7
1.4
—
—
—
0
0
12
54
2.33
1.79
1.7
1.5
—
—
—
0
0
0
46
0.00
1.74
0.0
1.5
—
39.63
—
0
46
85
692
1.51
1.73
5.3
3.9
6.46
6.49
mmol/l
0.05
80
631
5
13
3.94
1.73
1.0
2.5
—
—
—
0
0
5
13
3.94
1.73
1.2
2.1
—
—
—
0
0
5
13
3.94
1.73
1.2
2.1
—
—
—
0
0
5
13
3.94
1.73
1.2
2.1
—
—
—
0
0
5
14
3.65
1.63
3.6
2.2
106.80
105.21
mmol/l
—
5
14
10
43
2.42
1.62
2.7
2.2
—
—
—
0
0
109
942
1.54
1.62
4.3
3.8
14.84
14.51
pmol/l
0.70
98
880
7
26
2.77
1.60
1.6
1.8
—
—
—
0
0
7
27
2.67
1.53
4.3
1.2
—
—
—
0
0
13
67
2.03
1.43
2.9
3.5
62.66
74.27
ng/l
0.28
13
61
52
400
1.45
1.33
2.3
1.8
92.06
93.74
pmol/l
0.09
36
200
8
34
2.43
1.31
1.5
1.2
—
—
—
0
0
69
561
1.42
1.30
3.0
2.3
—
—
—
0
0
10
50
2.07
1.19
6.6
2.5
50.78
53.77
%
—
10
50
124
1133
1.48
1.13
4.9
4.4
1.75
1.83
mu/l
0.31
112
1050
25
173
1.53
1.06
2.4
2.9
2.42
2.45
mmol/l
0.66
25
156
27
191
1.50
1.04
4.6
3.0
199.75
206.28
ng/l
0.01
20
135
13
77
1.75
0.98
1.7
1.4
—
—
—
0
0
9
154
0.56
0.94
1.3
1.8
—
—
—
0
0
35
266
1.41
0.94
5.7
2.7
568.30
796.05
ng/l
0.86
29
220
8
42
1.95
0.90
2.5
1.9
—
—
—
0
0
101
908
1.33
0.88
3.5
3.5
—
—
—
0
0
8
46
1.78
0.84
3.0
1.5
—
—
—
0
0
20
141
1.48
0.79
3.9
1.7
27.72
29.19
s
0.84
20
135
146
1406
1.74
0.77
39.6
16.0
40.25
40.70
%
0.63
140
1340
10
60
1.71
0.74
1.3
1.3
—
—
—
0
0
25
188
1.39
0.72
1.4
2.2
—
—
—
0
0
38
307
1.32
0.70
4.6
3.5
13.42
8.33
mg/mmol
0.31
25
188
8
51
1.60
0.61
5.8
2.1
26.88
24.84
mmol/l
—
8
51
8
53
1.54
0.59
1.8
1.7
—
—
—
0
0
15
110
1.40
0.51
8.1
5.5
12.07
12.65
kpa
0.25
15
104
15
110
1.40
0.51
8.3
5.6
4.85
5.19
kpa
0.60
15
103
5
85
0.57
0.46
1.4
2.1
—
—
—
0
0
7
49
1.45
0.46
2.1
1.3
—
—
—
0
0
16
121
1.36
0.46
8.5
5.6
102.87
104.44
mmol/l
0.64
16
121
34
290
1.22
0.41
1.3
1.2
2.61
1.96
u/ml
—
7
83
0
15
0.00
0.41
0.0
1.3
—
—
—
0
0
22
183
1.24
0.34
2.4
1.6
438.06
431.27
pmol/l
0.06
17
161
20
233
0.84
0.26
3.4
3.8
18.68
21.71
%
—
10
91
8
103
0.76
0.22
1.4
2.1
—
—
—
0
0
0
11
0.00
0.21
0.0
1.2
—
224.65
—
0
11
0
10
0.00
0.21
0.0
1.1
—
—
—
0
0
35
319
1.13
0.20
2.1
1.7
1.68
1.36
mmol/l
1.06
27
280
117
1137
1.12
0.20
4.6
4.8
36.88
38.76
mmol/mol
2.12
109
1073
6
50
1.21
0.20
4.7
2.0
1.12
1.29
%
—
6
50
6
51
1.18
0.19
1.2
1.4
—
—
—
0
0
6
51
1.18
0.19
1.2
1.4
—
—
—
0
0
6
51
1.18
0.19
1.2
1.4
—
—
—
0
0
19
168
1.15
0.16
1.5
2.0
—
—
—
0
0
8
95
0.83
0.14
1.3
1.5
—
—
—
0
0
16
179
0.88
0.13
3.3
2.5
0.53
0.71
ug/l
—
9
102
122
1242
0.91
0.13
4.6
4.0
1.53
1.49
mmol/l
0.46
114
1163
6
55
1.09
0.09
1.2
1.6
—
—
—
0
0
123
1247
0.93
0.08
4.6
4.0
4.80
4.77
mmol/l
0.12
115
1174
122
1207
1.05
0.05
4.6
3.6
1.28
1.25
mmol/l
0.22
114
1117
126
1261
1.00
0.00
4.8
4.3
2.87
2.86
mmol/l
0.08
117
1181
26
265
0.98
0.00
1.4
1.4
—
—
—
0
0
119
1185
1.02
0.00
4.3
4.0
5.55
5.80
mmol/l
2.66
110
1109
10
98
1.02
0.00
2.6
3.9
1.22
10.04
ug/l
—
5
82
14
138
1.02
0.00
5.7
5.7
—
—
—
0
0
0
6
0.00
0.00
0.0
1.0
—
—
—
0
0
(40770918) von Willebrand factor (vWf).activity actual/normal in Platelet poor plasma by Immunoassay
0
6
0.00
0.00
0.0
2.8
—
111.00
—
0
6
0
6
0.00
0.00
0.0
1.2
—
7.17
—
0
6
0
6
0.00
0.00
0.0
1.0
—
—
—
0
0
0
6
0.00
0.00
0.0
1.5
—
22.27
—
0
6
6
67
0.89
0.00
1.3
1.0
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
7
0.00
-0.00
0.0
1.1
—
—
—
0
0
0
5
0.00
-0.00
0.0
2.2
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
5
0.00
-0.00
0.0
2.2
—
—
—
0
0
0
7
0.00
-0.00
0.0
1.4
—
—
—
0
0
Mortality – FinRegistry
↥Association
Association between endpoint STILL_ADULT and mortality.
Females
| Parameter | HR [95% CI] | p-value |
|---|---|---|
| STILL_ADULT | 1.988 [1.4, 2.83] | < 0.001 |
| Birth year | 0.999 [0.99, 1.01] | 0.737 |
During the follow-up period (1.1.1998 — 31.12.2019), 53 out of 328 females with STILL_ADULT died.
Males
| Parameter | HR [95% CI] | p-value |
|---|---|---|
| STILL_ADULT | 1.642 [1.18, 2.28] | 0.003 |
| Birth year | 0.988 [0.98, 1.0] | 0.009 |
During the follow-up period (1.1.1998 — 31.12.2019), 57 out of 253 males with STILL_ADULT died.
Mortality risk
Mortality risk for people of age
years, who have STILL_ADULT.| N-year risk | Females | Males |
|---|---|---|
| 1 | 0.161% | 0.335% |
| 5 | 1.301% | 1.57% |
| 10 | 3.268% | 4.225% |
| 15 | 6.061% | 8.388% |
| 20 | 10.759% | 14.54% |
Relationships between endpoints
↥Index endpoint: STILL_ADULT – Adult-onset Still disease
GWS hits: 1
Endpoint
Case Overlap
Survival Analysis
Genetic Correlations
Genetic Signals
N (Jaccard index)
HR [CI]
rg [CI]
Hits
Coloc Hits
FinRegistry
FinnGen
FinRegistry
FinnGen
FinnGen
Loading data